Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.56 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736813 | 1.00 | PRCP (0.56) | PRCPGRM5SLC6A9NAMPTNT5E | |
| SCHEMBL14737070 | 0.91 | PRCP (0.54) | PRCPGRM5SCD5NTRK1NPC1 | |
| SCHEMBL12184228 | 0.90 | PRCP (0.56) | PRCPGRM5SLC6A9NAMPTNT5E | |
| SCHEMBL12183916 | 0.90 | PRCP (0.58) | PRCPGRM5SLC6A9NAMPTNT5E | |
| SCHEMBL12184137 | 0.90 | PRCP (0.56) | PRCPGRM5SLC6A9NAMPTNT5E | |
| SCHEMBL14749314 | 0.90 | PRCP (0.58) | PRCPGRM5SLC6A9NAMPTNT5E | |
| SCHEMBL12184583 | 0.88 | PRCP (0.52) | PRCPNT5E | |
| SCHEMBL14737198 | 0.83 | PRCP (0.55) | PRCP | |
| SCHEMBL14749294 | 0.81 | PRCP (0.47) | PRCPGRM5NTRK1NPC1RAB9A | |
| SCHEMBL14749284 | 0.81 | PRCP (0.49) | PRCPGRM5NTRK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885GRM5 3785/4885SLC6A9 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.